Gildan Activewear Inc. (GIL)

Gildan Activewear Inc. (GIL)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gildan Activewear Inc. (“Gildan” or “the Company”) (NYSE: GIL). Investors who purchased Gildan securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Gildan has violated federal securities laws.

Investigation Details:
On December 11, 2023, Gildan issued a press release “announc[ing] that Glenn J. Chamandy has left his position as President and Chief Executive Officer and director of the Company. Vince Tyra has been appointed President and CEO effective February 12, 2024.” Also on December 11, 2023, Chamandy issued a separate statement to the effect that he had learned only the previous day that the Company’s Board of Directors “was terminating [his] employment agreement without cause.” Following news of Chamandy’s departure, Gildan’s stock price fell $3.94 per share, or 10.79%, to close at $32.58 per share on December 11, 2023.

What’s Next?
If you are aware of any facts relating to this investigation or purchased Gildan securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]